Now You Have the Freedom to Live Your Life

Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults. Single-dose Sitavig stops most cold sores before they start. For patients, this means fewer outbreaks– and more time to be yourself.1

Cold sores are caused by the herpes simplex virus (HSV-1), which lies dormant until awakened by a triggering event such as injury, trauma, hormonal changes, major event stressors, daily life stressors, sun exposure and illness.

When the virus first starts replicating, you may experience a tingling, itching or burning sensation. At this stage, if you act immediately with the right treatment, you can potentially prevent a blister from forming. This may also reduce the severity of your cold sore, not to mention the time it takes to heal. Immediate treatment may also delay your next outbreak. Sitavig delivers concentrated medication that is localized at the site of viral replication in the mouth.

Knowledge is freedom when it comes to cold sores. Know your triggers and stop outbreaks before they happen.

1. Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, Boutolleau D, Attali P and the LIP Study Group. Efficacy and safety of acyclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP): A double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014;13(7):791-798.

Click Here to download your Sitavig® Rx Prescription Pad. Clicking this link will automatically download the PDF file.


Indication & Important Safety Information

INDICATION
Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.

IMPORTANT SAFETY INFORMATION

  • Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product.
  • Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients.
  • Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal.
  • In a controlled clinical trial Sitavig's most common side effects (greater than or equal to 1%) were: headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch.com or call 1-800-FDA-1088. Click here for Full Prescribing Information.

SIT-WEBFS-0119